Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2023-10-26 DOI:10.1155/2023/1793535

Luca Mastorino, Valentina Celoria, Nicole Macagno, Caterina Cariti, Sara Susca, Niccolò Siliquini, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Lorenza Burzi, Pietro Quaglino, Simone Ribero, Paolo Dapavo

{"title":"Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study","authors":"Luca Mastorino, Valentina Celoria, Nicole Macagno, Caterina Cariti, Sara Susca, Niccolò Siliquini, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Lorenza Burzi, Pietro Quaglino, Simone Ribero, Paolo Dapavo","doi":"10.1155/2023/1793535","DOIUrl":null,"url":null,"abstract":"Introduction. Psoriasis of the scalp, genital areas, and palms and soles represents a treatment challenge in clinical practice. Randomized clinical trials and real-life studies investigating the efficacy of biological drugs in these sites are scarce. The present is a descriptive retrospective real-life study with the aim to evaluate the efficacy and safety of brodalumab in these difficult-to-treat areas. Materials and Methods. 158 psoriatic patients with scalp involvement, 69 with genital involvement, and 54 with palmoplantar involvement being treated with brodalumab were assessed at weeks 16, 28, and 48 using PSSI (Psoriasis Scalp Severity Index), sPGA-G (Physician Global Assessment of Genitalia), and ppPASI (Palmoplantar Psoriasis Area and Severity Index). Results. The achievement of relative PSSIs (75%, 90%, and 100%) was already observed in week 16. 86% achieved PSSI75, 80% PSSI90, and 75% PSSI100. The sPGA-g 0/1 was achieved by 83% of patients at week 16 and 100% at week 24 and 48. At week 16 ppPASI75, 90, and 100 were all reached by 76.9% of patients; at week 24, 84.6% of patients reached all relative ppPASI. Conclusions. Brodalumab proved to be effective and safe in the treatment of scalp, genital, and palmoplantar regions.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"31 24","pages":"0"},"PeriodicalIF":3.7000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/1793535","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction. Psoriasis of the scalp, genital areas, and palms and soles represents a treatment challenge in clinical practice. Randomized clinical trials and real-life studies investigating the efficacy of biological drugs in these sites are scarce. The present is a descriptive retrospective real-life study with the aim to evaluate the efficacy and safety of brodalumab in these difficult-to-treat areas. Materials and Methods. 158 psoriatic patients with scalp involvement, 69 with genital involvement, and 54 with palmoplantar involvement being treated with brodalumab were assessed at weeks 16, 28, and 48 using PSSI (Psoriasis Scalp Severity Index), sPGA-G (Physician Global Assessment of Genitalia), and ppPASI (Palmoplantar Psoriasis Area and Severity Index). Results. The achievement of relative PSSIs (75%, 90%, and 100%) was already observed in week 16. 86% achieved PSSI75, 80% PSSI90, and 75% PSSI100. The sPGA-g 0/1 was achieved by 83% of patients at week 16 and 100% at week 24 and 48. At week 16 ppPASI75, 90, and 100 were all reached by 76.9% of patients; at week 24, 84.6% of patients reached all relative ppPASI. Conclusions. Brodalumab proved to be effective and safe in the treatment of scalp, genital, and palmoplantar regions.

查看原文本刊更多论文

Brodalumab治疗头皮、掌跖和生殖器牛皮癣的有效性:一项描述性试点研究

介绍。头皮、生殖器、手掌和脚底的牛皮癣是临床实践中的一个治疗挑战。调查生物药物在这些部位疗效的随机临床试验和实际研究很少。目前是一项描述性回顾性现实研究，目的是评估brodalumab在这些难以治疗地区的疗效和安全性。材料和方法:在第16周、28周和48周，使用PSSI(牛皮癣头皮严重指数)、sPGA-G(生殖器内科整体评估)和ppPASI(掌跖牛皮癣面积和严重指数)对158例头皮受累的银屑病患者、69例生殖器受累的银屑病患者和54例掌跖受累的银屑病患者进行评估。结果。在第16周已经观察到相对pssi(75%， 90%和100%)的实现。86%达到PSSI75, 80%达到PSSI90, 75%达到PSSI100。在第16周，83%的患者达到了sPGA-g 0/1，在第24周和第48周达到了100%。第16周，76.9%的患者均达到ppPASI75、90和100;在第24周，84.6%的患者达到所有相对ppPASI。结论。事实证明，Brodalumab在治疗头皮、生殖器和掌足底区域是有效和安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.